Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 4:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Autoinjector (AI) Device Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Bioequivalence of Tocilizumab Following Subcutaneous Administration Via an Autoinjector (AI 1000-G2) Versus a Pre-Filled Syringe in Healthy Volunteers

NCT02678988
View directory record Official record
Conditions
Healthy Volunteer
Interventions
AI-1000 G2, PFS-NSD, Tocilizumab
Device · Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
189 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
3
States / cities
Lenexa, Kansas • Marlton, New Jersey • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 2, 2026, 4:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Accessorised Prefilled Syringe to an Autoinjector Pharmacokinetic Bridging Study of Tozorakimab

NCT06908577
View directory record Official record
Conditions
Healthy Participants
Interventions
Tozorakimab, Autoinjector (AI) Device, Accessorised Prefilled Syringe (APFS) Device
Drug · Device
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
254 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Sep 2, 2026, 4:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Pilot Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Autoinjector (PFS+AI) in Healthy Participants

NCT03961295
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Vedolizumab SC
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Sep 2, 2026, 4:28 PM EDT
Completed Phase 3 Interventional Results available

Tezepelumab Home Use Study

NCT03968978
View directory record Official record
Conditions
Asthma
Interventions
Tezepelumab (APFS), Tezepelumab (AI)
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 80 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
16
States / cities
Hoover, Alabama • Gilbert, Arizona • Northridge, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Sep 2, 2026, 4:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Injections of LY3074828 in Healthy Participants

NCT03886948
View directory record Official record
Conditions
Healthy
Interventions
LY3074828, Pre-filled syringe (PFS), Autoinjector (AI)
Drug · Device
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Feb 19, 2024 · Synced Sep 2, 2026, 4:28 PM EDT
Completed Phase 3 Interventional Results available

A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis

NCT03432533
View directory record Official record
Conditions
Post-Menopausal Osteoporosis
Interventions
romosozumab HCP administration with PFS, romosozumab self-administration with AI/Pen
Drug · Device
Lead sponsor
Amgen
Industry
Eligibility
55 Years to 90 Years · Female only
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
35
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced Sep 2, 2026, 4:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Find Out How Litifilimab is Processed in the Body in Healthy Participants When Given Under the Skin in 3 Different Ways

NCT06741657
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Litifilimab, AI, OBI, PFS
Drug · Device
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
404 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Las Vegas, Nevada • Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 2, 2026, 4:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare the Pharmacokinetics of CSL312 Administered by Prefilled Syringe Assembled to Autoinjector to the Pharmacokinetics Administered by Prefilled Syringe Assembled to Needle Safety Device in Healthy Subjects

NCT05306275
View directory record Official record
Conditions
Healthy Participants
Interventions
CSL312
Drug
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years to 55 Years
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Sep 2, 2026, 4:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Autoinjector (PFS+AI) in Healthy Participants

NCT03961308
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Vedolizumab SC
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
204 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Tempe, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Sep 2, 2026, 4:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Lebrikizumab (LY3650150) Administered by Two Different Devices in Healthy Participants

NCT04840901
View directory record Official record
Conditions
Healthy
Interventions
Lebrikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
242 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
4
States / cities
Daytona Beach, Florida • Springfield, Missouri • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Sep 2, 2026, 4:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Two Formulations of LY3074828 in Healthy Participants

NCT03662100
View directory record Official record
Conditions
Healthy
Interventions
LY3074828, LY3074828, Auto-injector (AI), Prefilled syringe (PFS)
Biological · Drug · Device
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Sep 2, 2026, 4:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Accessorized Pre-Filled Syringe to Autoinjector Pharmacokinetic Bridging Study in Anifrolumab

NCT05339100
View directory record Official record
Conditions
Healthy Participants Study
Interventions
Anifrolumab, Autoinjector, Accessorized Pre-Filled Syringe
Drug · Device
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Sep 2, 2026, 4:28 PM EDT
Completed Phase 3 Interventional Results available

Usability of an AI for M923 in Subjects With Moderate to Severe RA

NCT02722044
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
M923, Autoinjector
Biological · Device
Lead sponsor
Momenta Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Detroit, Michigan • Greensboro, North Carolina • Oklahoma City, Oklahoma + 3 more
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Sep 2, 2026, 4:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Different Injectable Formulations of LY3375880 in Healthy Participants

NCT03913260
View directory record Official record
Conditions
Healthy
Interventions
LY3375880, Buffer Matrix (No LY3375880), Autoinjector (AI), Manual Syringe
Drug · Device
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 10, 2019 · Synced Sep 2, 2026, 4:28 PM EDT